TCL Archive Freestanding Cancer Centers May Be The “Missing Ingredient In Cancer Treatment,” DeVita Believes January 11, 1985
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive Survival Rates Same For Two Treatments For Eye Cancer: Radiation Or Removal July 27, 2001
